Lee Martin
About Lee Martin
Lee Martin is the Senior Manager of Clinical Compliance at BeiGene in Fremantle, Western Australia, with over 15 years of experience in clinical research and compliance.
Company
Lee Martin is currently employed at BeiGene, a global biotechnology company that focuses on developing molecularly targeted and immuno-oncology drug candidates for cancer treatment. He works in Fremantle, Western Australia, Australia, as a Senior Manager in Clinical Compliance.
Title
Lee Martin holds the position of Senior Manager, Clinical Compliance, at BeiGene. In this role, he oversees clinical compliance activities and ensures adherence to clinical regulation standards.
Background
Lee Martin has accumulated over 15 years of experience in clinical research and compliance. His career began at Progen Pharmaceuticals, where he worked as a Clinical Research Associate (CRA) from 2005 to 2007. He then joined Trident Clinical Research as CRA from 2008 to 2009. Lee also previously held the positions of Senior CRA at i3 Innovus from 2008 to 2011 and Clinical Quality Control Assessor and Process Manager at Covance, where he worked from 2011 to 2020 in Brisbane, Australia.
Experience at Covance
Lee Martin spent a significant portion of his career at Covance, contributing to various roles for a total of 9 years. From 2011 to 2020, he held positions including Clinical Quality Control Assessor and Process Manager. His responsibilities involved overseeing clinical quality control and managing clinical processes in research activities.
Clinical Research Expertise
Throughout his career, Lee Martin has demonstrated extensive expertise in clinical research. He has worked across diverse roles such as Clinical Research Associate (CRA), Senior CRA, and Process Manager. His background includes experience in both clinical research organizations and pharmaceutical companies, and he has been engaged in clinical quality control and process management. Lee's career has taken him to multiple cities in Australia, notably Brisbane and Fremantle.